NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
Clinical Trials
7 trialsNCT02659514 2022-03-11
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02418689 2022-01-20
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT02544997 2020-07-07
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Samsung Medical Center
Phase 2 Completed
NCT02979821 2018-05-24
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Korean Association for the Study of Targeted Therapy
Phase 2 Completed
NCT01455571 2014-02-26
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT01455584 2013-05-23
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed